Dr Angela Garner

Angela Garner MD

Dr. Angela Garner, MD, has been practicing medicine for over 20 years. Dr. Garner is an internist and a hospice director. She has always been passionate about helping others as she enjoys volunteering her time in other countries to help people get the medical care they need.

Dr. Garner believes that feeling beautiful inside and out has tremendous benefits to the overall aging process. In 2012, she opened Refresh Medical Day Spa and Hormonal Health in Overland Park, KS. Also, in 2012, Dr. Garner wanted to combine her passion to help others with her medical expertise when she joined LifeWorks.


University of Missouri – Kansas City, Kansas City, MO.

Residency Program – Internal Medicine  2002 – 2005

                      Saba University School of Medicine, Saba, N.A.,

Graduated May 2002

  •  President, Student Government Association, August 1998 – August 1999
  •  Certified Hyperbaric Medicine Technician, June 1998 – August 1999
  •  President of Class, January 1998 – July 1998
  •  Basic Sciences Tutor, 1998
  • Gross Anatomy Laboratory Teaching Assistant, June 1998-August 1998

St. Mary’s of the Plains College, Wichita, KS; Graduated May 1985

Bachelor of Science in Nursing

Graduate Cum Laude, 1985

Licensure May 1985

Secretary of Student Council

Donnelly College, Kansas City, KS; September 1994 – April 1995

Pre-med courses


Wichita State University, Wichita, KS; September 1993 – May 1994

Pre-med courses

Prerequisites for Nursing; September 1981 – May 1983:



  • Kansas State Medical License 2008
  • American Board of Disability Analysts – Disability Analyst & Fellow 2008
  • Missouri State Medical License 2005
  • Kansas State Medical License 2005
  • Board Certified – Internal Medicine 2005
  • Diplomate of American Academy of Pain Management 2011
  • Fellow of American College of Physicians 2011
  • Board Certified- Hospice and Palliative Care 2012
  • Board Certified Hospice Medical Director 2014


  • American Medical Association
  • American College of Physicians
  • American Academy of Pain Management
  • American Society of Pain Educators
  • American Society of Pain


  • Gold Humanism Honor Society

Professional Development:

  •  CME: Sickle Cell Conference; April 2006; Memphis, TN
  •  CME: Sickle Cell Conference; September 2008; New Orleans, LA
  •  CME: Pain Management Conference; September 2008; Nashville, TN


  •  KCUMB Annual Winter CME Seminar; Kauffman Foundation Conference Center: “Treatment of Chronic Pain in the Adult/Geriatric Patient”; Dec. 6, 2008
  •  Summer Seminar for Senior Medical Students: Kansas City University of  Medicine and Biosciences:  “Chronic Pain Management”; July 9, 2008
  • Keynote speaker at American Heart Association Bi-State Stroke Consortium “Physiological Impact Sickle Cell Disease on Stroke”; January 17, 2008
  • Noon Conference; Sickle Cell Anemia; UMKC – School of Medicine; December 5, 2007 summer Seminar for Senior Medical Students: Kansas City University of Medicine and Biosciences:  “Chronic Pain Management”; July 2007
  • CME SeminarButterworth Alumni Center, Kansas City University of Medicine and Biosciences:  “Finding the Treatment that Fits You and Your Patient”; March 3, 2007
  • CME Event: Grand Rounds: Chronic Pain; UMKC – School of Medicine; January 12, 2007 Winter
  • CME Seminar; Kansas City University of Medicine and Biosciences “Management of Chronic Pain in the Adult: Making it Work for You and Your Patient”; Dec. 14, 2006
  • Noon Conference: TMC – Lakewood; Sickle Cell Disease; November 28, 2006
  • Lecture on Chronic Pain Management to Senior Medical Students; Kansas City University of Medicine & Bio-Sciences; July 18, 2006
  • Noon Conference; Sickle Cell Anemia; Nov. 2, 2005; UMKC-School of Medicine


Principal Investigator:

Novartis Pharmaceuticals trial entitled: “An 8-week Multicenter, Randomized, Double-           blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy            and Safety of Aliskiren / Amlodipine / HCTZ compared to Aliskiren / Amlodipine in US            Minority Patients with Stage 2 Hypertension”  Protocol Number: CSPA100AUS02 – 2009 – 2010

Research: Principal Investigator continued:

Anthera Pharmaceuticals, Inc.: IMPACTS Trial: “Investigation of the modulation of phospholipase in acute chest syndrome.  (Dose escalation study: varespladib infusion [A-001] for the prevention of acute chest syndrome in at-risk patients with sickle cell disease and vaso-occlussive crisis.)”  5/2007 – 2008

Novartis Pharmaceuticals trial entitled: A multicenter, randomized, double blind, parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen of Exforge in patients uncontrolled on ARB monotherapy. Protocol No.: VAA489AUS02 2008 – 2008

Novaris Pharmaceuticals trial entitled:  An 8 week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive   Efficacy and Safety of Aliskiren Administered in Combination with Valsartan versus Valsartan alone in Hypertensive Patients with Type 2 Diabetes Mellitus. Protocol Number: CSPV100AUS02 2010 – ongoing  

Sub-Investigator :

Sanofi-Aventis: Protocol No: DFI 6032 Entitled: “A double-blind, randomized, parallel-group, dose ranging, multicenter study to evaluate the efficacy and safety of 2.5, 10, 35, and 50 mg AVE 7688 once daily, using  100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertension”    2006 – 2008

Sanofi-Aventis:  Protocol number: EFC5826  “Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors”    2006 –  2009

Novartis Pharmaceuticals trial entitled:  An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of Valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.  Protocol Number: CVEA489A2302  2006 – 2007

Novartis Pharmaceuticals trial entitled: “A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with Vildagliptin 100 qd to Placebo as Add-On Therapy in patients with Type 2 Diabetes adequately controlled with Metformin Monotherapy” Protocol No.: CLF237A23103  2006 – 2007

Norvartis Pharmaceuticals trial entitled: “A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherapy components in drug naïve patients with type 2 diabetes” Protocol No.: CLMF237A2302 2007 – 2008

Research: Sub-investigator continued:

Novartis Pharmaceuticals trial entitled: “A multicenter, open-label sub-study to LMF237A2302 to assess the effect of 24 weeks treatment with initial combination of vildagliptin 100 mg qd plus metformin 1000 mg bid in drug naïve patients with type 2 diabetes with very poor glycemic control” Protocol No.: CLMF237A2302S1    2007 – 2008

Pfizer – “A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen” Protocol no.: A3191172  2007 – ongoing

Ranibizumab for neovascularization in sickle cell retinopathy:  A Phase I study. Study Drug: Recombinant humanized anti-VEGF monocional antibody fragment (rhuFab V2 [ranibizumab])   2007 – ongoing.

Novartis Pharmaceuticals trial entitled:  A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in patients with essential hypertension. Protocol No.: CSPP100A2404  2008 – 2009

Research – Other: 

 Assisting in the collection of data for University of Tennessee Health Science Center for project entitled “Quality of Life in Sickle Cell Disease”.  2007 – ongoing


Encyclopedia of Global Health: Volumes 1 – 4; Yawei Zhang – General Editor SAGE Publications; 2008 Text articles: Digestive Diseases (General); Vol 2: pgs. 528-531

Hypoglycemia; Vol. 2: pgs. 874-875 [with Christina Murray]

Burns; Vol. 1: pgs. 321-323 [with Christina Murray]

Nausea and Vomiting; Vol. 3: pgs. 1210-1212 [with Christina Murray]

Constipation; Vol 1: pgs. 447-448

Spleen Diseases; Vol. 4: pgs. 1597-1598 [with Ryan Strain]

Sun Exposure; Vol. 4: pgs. 1629-1630 [with Ryan Strain]

Glomerular Diseases; Vol. 2: pgs. 744-745

Nephrology; Vol. 3: pgs. 1218-1219

Nephrologist; Vol. 3: pgs. 1217-1218

Hematologist; Vol. 2: pgs. 822-823

Hemocromatosis; Vol. 2: pgs. 825-826 [with Melissa Meiners]

Blood/Blood Transfusions; Vol. 1: pgs. 270-272

Lean Body Mass; Vol. 3: pgs. 998-999

Carcinoid Tumors; Vol. 1: pgs. 344-345

Fractures; Vol. 2: pgs. 685

Internist; Vol. 2: pgs. 943-944

Body Surface Area; Vol. 1: pgs. 273-274

Calcium; Vol. 1: pgs. 331-332

Myositis; Vol. 3: pgs. 1157-1158

Dialysis; Vol. 2: pg. 521

Kidney Failure and Dialysis; Vol. 3: pgs. 575-576

Angioplasty; Vol. 1: pgs. 140-141

Cellulitis; Vol. 1: pgs. 358-359 [with Erin Eisenhardt]

Community Involvement:


  • Community Education Lectures presented to the Saba Lion’s Club, sponsored by the Saba University Student Government Association; January 1998-August 1999
  • Coordinator of Social Events for Medical Students and Saba Community;        August 1998- August 1999
  • Coordinator of Tutoring Sessions for Saba High School Children;        January 1998- April 1999
  • Coordinator for clean up in Hurricane George, September 1998
  • Coordinator of Blood Pressure/Blood Glucose Screen for Saba Community June 1999
  • Honored at Saba Lion’s Club Meeting for Community Service; June 1999
  • Coordinator of Volunteers for Saba Carnival, June 1998

Committee Service:

  • Selection Committee – UMKC – School of Medicine; June 2005 – June 2012
  • Corporate Pain Committee – Truman Medical Center; July 2005 – June 2012
  • Utilization Management; Truman Medical Center; July 2006 – June 2012

Career Interests:      

Hospice and Palliative Care Preventative Medicine, Pain Management, Sickle Cell Disease issues